In brief: Select Vaccines, Psiron, Visiomed

By Graeme O'Neill
Thursday, 21 April, 2005

Select Vaccines' (ASX:SLT) hepatitis E diagnostics kits have gained CE Mark approval for sale in the European Union. The company will sell the kits from June this year through its licencee, Genelabs

Psiron (ASX:PSX) has presented new data at a US medical conference confirming the anti-cancer effect in in vitro trials of its Coxsackievirus A21 virotherapy in cancer cell lines for breast, prostate and colon cancer and multiple myeloma.

Visiomed (ASX:VSG) subsidiary InfaMed has begun to sell its Funhaler children's asthma spacer device in Australian pharmacies.

Content from other channels on our network

Gilmour Space opens office in South Australia

Cyber risk is rising faster than Australian manufacturers can respond

Fortescue commissions first battery electric locomotives

Electric actuation: a gamechanger for upstream processes

Government seeks input on wind and transmission infrastructure

Why physical device security is becoming a patient privacy issue in health care

Food waste in Australian hospitals and aged care homes — can AI help?

Legislation introduced to improve private health choice and transparency

WA healthcare professionals gain workplace-specific courses

InterSystems Honoured with Four 2026 Best in KLAS Awards

Liquid metal to 'harvest' clean hydrogen from water

Epson makes progress with sustainability plans and initiatives in Australia and New Zealand

Sustainable wastewater treatment achieved for urban areas

'Brownfielding' increases to meet metal demand

NSW to exceed energy storage targets

In brief: Select Vaccines, Psiron, Visiomed

Noxopharm says paper reveals science behind its immune system platform

Neurosensing/neurostimulation implants session to be held on Monday

argenx and Monash University partner against autoimmune diseases

Content from other channels on our network